Credit: Shutterstock photoAuris Medical, a biotech developing treatments for tinnitus and other inner ear disorders, raised $56 million by offering 9.4 million shares at $6, consistent with the revised terms filed with the SEC on Tuesday. Auris Medical plans to list on the NASDAQ under the symbol EARS. Auris Medical initially filed confidentially on 3/18/2014. Jefferies & Co. and Leerink Partners acted as lead managers on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
